TNF inhibitors should be used in patients with heart failure only after consideration of other treatment options.
TNF inhibitors are contra-indicated in patients with a personal or family history of multiple sclerosis or demyelinating disease.
TNF inhibitors should not be administered to patients with moderate to severe heart failure (New York Heart Association Functional Class III/IV).
- TRADE NAME: Cimzia (Celltech, UCB)
- INDICATIONS: Crohn’s disease, rheumatoid arthritis
- SYNONYM: Certolizumab pegol
- CLASS: Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist), Biologic, Disease-modifying antirheumatic drug (DMARD), Monoclonal antibody
- HALF-LIFE: 14 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Anakinra, Lenalidomide, Live vaccines, Natalizumab, Rituximab - PREGNANCY: Limited evidence insufficient to inform drug-associated risk
- See adverse reactions attributed to class:
Anti-Tumor Necrosis Factor-alpha (TNF-α antagonist)
SERIOUS INFECTIONS AND MALIGNANCY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 05/20/2024
